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Background: Massive blood loss in obstetrics is often the cause of the development 
of coagulopathy and uncontrolled coagulopathic bleeding. These complications in the 
intersectional period are one of the main causes of the development of multiple organ failure 
syndrome and lead to a significant increase in the duration of hospitalization in the intensive 
care unit (Sohn C.H., 2017). At present, many clinicians consider the prothrombin complex 
concentrates (PCC) as a serious alternative to the use of fresh frozen plasma (FFP) in 
coagulopathies due to hepatic insufficiency and bleeding in various etiologies (Peyvandi F. et 
al. 2013; Collis R.E. et al. 2015).  
The use of PCC in cases of severe coagulopathy (not associated with oral 
anticoagulants) has been described. These agents have been used for some time in some 
European countries (Klein A.A. et al., 2016). The scientific rationale is that coagulopathy can 
result from low concentrations of clotting proteins leading to a failure of adequate thrombin 
production and failure to initiate and maintain coagulation. Agents such as FFP allow the 
administration of these clotting proteins but only in a dilute form (reflecting normal 
population concentrations but no greater). As described earlier, FFP may lack efficacy in 
reversing established coagulation defects. PCC may help to restore thrombin production by 
providing (as inactive zymogens) those clotting factors most critical to coagulation: 
principally in restoring prothrombin concentration. This is supported by experimental 
research and observational studies. European Society of Anaesthesiology (ESA) guidelines on 
management of massive bleeding support the use of PCC (at a dose of 20–30 IU/kg) in adults 
(Kozek-Langenecker S.A. et al., 2017). 
Obstetrical hemorrhage is the most common cause of maternal mortality worldwide. 
Together with adequate surgical control and judicious transfusion of blood products, the use 
of pharmacological agents (e.g., tranexamic acid) and clotting factor concentrates (e.g., 
fibrinogen concentrates and prothrombin complex concentrates) results in improved 
hemostasis and decreased bleeding-associated mortality. Guidance in the administration of 
these agents with the use of viscoelastic testing will likely become standard of care in the near 
future (Luis D. et al., 2018). 
Objective: Evaluate the state of hemodynamics, water sectors, hemostasis, the 
frequency and severity of clinical manifestations of multiple organ failure (MOF) in the use of 
PCC in the treatment of massive obstetrical bleeding. 
Methods: This was a multicenter, retro-prospective study of PCC, conducted in 5 
perinatal сenters in the Dnipropetrovsk region over a period from January 2006 to December 
2017. After approving the research design, the ethics committee examined 248 women, in 
which the labor or early postpartum period was complicated by acute severe blood loss with a 
blood volume deficit of 40-60%. Depending on the characteristics of intensive care  patients 
were divided into 2 groups. In group 1 (n = 150), standard therapy of acute blood loss was 
performed according to clinical protocols of the Ministry of Health of Ukraine. In the 2nd 
group (n = 98), the PCC (Octaplex, 1000-1500 IU) was added to the treatment. The groups 
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were comparable with demographic indicators, the term of delivery, the volume of blood loss. 
Evaluated: the number of erythrocytes, hemoglobin, hematocrit, prothrombin index, 
fibrinogen, INR; water sector of the organism (total volume of fluid, volume of extracellular, 
intracellular and interstitial fluid) non-invasive - integral impedance method; clinical signs of 
MOF. Control points: 12 hours, 1, 3, 5, 7, 10, 14 and 28 days after delivery.  
Clinical effectiveness was assessed by descriptive statistics in keeping with the 
primary and secondary objectives. The treatment was considered effective when a rating of 
very good or satisfactory was provided by the investigator. Results are presented as mean and 
standard deviation for parameters following the normal distribution and median and 
interquartile range for nonnormal distributions. 
Results: With the use of PCC there was a decrease by 24.5% (p <0.01) of the total 
volume of infusion-transfusion media; a decrease of 22% (p <0.01) of plasma volume and 
9.1% (p <0.05) of erythrocyte volume. There was also a decrease in the frequency (in 5.1 
times, p <0.01) and the duration of vasopressor support (1,5 days, p < 0.01), mechanical 
ventilation (5.7 times, p < 0.01), was reduced as the number of patients requiring substitution 
renal therapy (2.9 times, p <0.01), and the duration of the latter (1.7 days, p < 0.01). The 
frequency of manifestations of gastrointestinal insufficiency declined more than 2 times. The 
levels of prothrombin index and fibrinogen corresponded to the norm at the end of 1 day of 
treatment. 
Conclusions:  The use of PCC in the transfusion therapy of acute blood loss forms a 
restrictive type of supplementation of the blood volume deficiency, which provides a reliable 
decrease in the frequency of clinical manifestations of multiple organ failure. The use PCC 
prevents the development and progression of coagulopathy in the treatment of massive 
obstetrical bleeding. 
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Problems of diagnostics and prognosis of the course of purulent-inflammatory 
diseases of the maxillofacial area at the moment remain relevant and still far from their final 
solution. In the last decade there is an increase in the number of patients with complicated 
atypical and long-term course of purulent-inflammatory process, which leads to loss of ability 
to work, increase in disability and increase fatal cases. 
The course and completion of inflammatory disease, according to domestic and 
foreign authors, in most cases is related to the age of patients, the presence of concomitant 
and background diseases, the state of the immune system, as well as the general hereditary 
background of the organism, which determines the nature of the reaction to one or another 
internal influence.  
At the given moment there is a significant amount of knowledge that can determine 
the important role in the development of various diseases of the destabilization of the genome. 
It is known that the "resistance" of the genetic apparatus of cells in infectious patients 
